Smart Nuclide
Latest round
- Series C
Last raised
- Jul 2021
Total raised
- $30M
Investors
- 10
About Smart Nuclide
Based in China and established in 2015, Smart Nuclide is a clinical-stage biopharmaceutical company that engages in the research and development of biological drug products for molecular nuclear oncology. The company’s FIH radiotherapeutic drug has received PCC (preclinical candidate compounds) certificate. It has established a Class B qualified radiopharmaceutical GMP workshop, and a branch office in Shanghai. The company has cooperated with Shanxi Medical University, Jiangsu Institute of Atomic Medicine, Shandong Cancer Hospital and other universities, research institutes and hospitals. Smart Nuclide provides products including recombinant human thyrotropin, tumor diagnostic radiographic drugs, and tumor therapeutic radiopharmaceuticals based on its single-domain antibody development platform and radionuclide coupling labeling platform. The company has deployed more than 10 innovative nuclide diagnostic and treatment product pipelines, and its main product is human thyroid-stimulating hormone. The company generates revenue by developing and selling products including recombinant human thyrotropin, tumor diagnostic radiographic drugs, and tumor therapeutic radiopharmaceuticals. Smart Nuclide will accelerate the launch of its human thyrotropin injection, clinical trials of innovative radioactive diagnostic drugs such as SNA002, and IND (Investigational New Drug) advancement of new target therapeutic nuclear drugs such as SNA014 and SNA025.
Who invested in Smart Nuclide
10 investors across 5 rounds
See all investors in Smart Nuclide
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Smart Nuclide
Who invested in Smart Nuclide?
Smart Nuclide has 10 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Smart Nuclide raised?
Smart Nuclide has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Smart Nuclide last raise money?
Smart Nuclide's most recent round on record is a Series C, in Jul 2021.
What does Smart Nuclide do?
Based in China and established in 2015, Smart Nuclide is a clinical-stage biopharmaceutical company that engages in the research and development of biological drug products for molecular nuclear oncology.
Where is Smart Nuclide headquartered?
Smart Nuclide is headquartered in Suzhou, China.
Which VCs invest in companies like Smart Nuclide?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Smart Nuclide's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Smart Nuclide? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.